196 related articles for article (PubMed ID: 37239866)
21. Cell-free circulating DNA integrity is an independent predictor of impending breast cancer recurrence.
Cheng J; Cuk K; Heil J; Golatta M; Schott S; Sohn C; Schneeweiss A; Burwinkel B; Surowy H
Oncotarget; 2017 Aug; 8(33):54537-54547. PubMed ID: 28903362
[TBL] [Abstract][Full Text] [Related]
22. Rapid and ultrasensitive detection of circulating human papillomavirus E7 cell-free DNA as a cervical cancer biomarker.
Rungkamoltip P; Temisak S; Piboonprai K; Japrung D; Thangsunan P; Chanpanitkitchot S; Chaowawanit W; Chandeying N; Tangjitgamol S; Iempridee T
Exp Biol Med (Maywood); 2021 Mar; 246(6):654-666. PubMed ID: 33307803
[TBL] [Abstract][Full Text] [Related]
23. Value of circulating cell-free DNA analysis as a diagnostic tool for breast cancer: a meta-analysis.
Lin Z; Neiswender J; Fang B; Ma X; Zhang J; Hu X
Oncotarget; 2017 Apr; 8(16):26625-26636. PubMed ID: 28460452
[TBL] [Abstract][Full Text] [Related]
24. Circulating cell-free DNA integrity as a diagnostic and prognostic marker for breast and prostate cancers.
Arko-Boham B; Aryee NA; Blay RM; Owusu EDA; Tagoe EA; Doris Shackie ES; Debrah AB; Adu-Aryee NA
Cancer Genet; 2019 Jun; 235-236():65-71. PubMed ID: 31105051
[TBL] [Abstract][Full Text] [Related]
25. Cell-Free Circulating DNA Integrity Based on Peripheral Blood as a Biomarker for Diagnosis of Cancer: A Systematic Review.
Cheng J; Tang Q; Cao X; Burwinkel B
Cancer Epidemiol Biomarkers Prev; 2017 Nov; 26(11):1595-1602. PubMed ID: 28830871
[No Abstract] [Full Text] [Related]
26. Quantitative assessment of copy number alterations by liquid biopsy for neuroblastoma.
Shirai R; Osumi T; Sato-Otsubo A; Nakabayashi K; Ishiwata K; Yamada Y; Yoshida M; Yoshida K; Shioda Y; Kiyotani C; Terashima K; Tomizawa D; Takasugi N; Takita J; Miyazaki O; Kiyokawa N; Yoneda A; Kanamori Y; Hishiki T; Matsumoto K; Hata K; Yoshioka T; Kato M
Genes Chromosomes Cancer; 2022 Nov; 61(11):662-669. PubMed ID: 35655408
[TBL] [Abstract][Full Text] [Related]
27. Circulating cell-free DNA: a promising marker of pathologic tumor response in rectal cancer patients receiving preoperative chemoradiotherapy.
Agostini M; Pucciarelli S; Enzo MV; Del Bianco P; Briarava M; Bedin C; Maretto I; Friso ML; Lonardi S; Mescoli C; Toppan P; Urso E; Nitti D
Ann Surg Oncol; 2011 Sep; 18(9):2461-8. PubMed ID: 21416156
[TBL] [Abstract][Full Text] [Related]
28. Estimation of ALU Repetitive Elements in Plasma as a Cost-Effective Liquid Biopsy Tool for Disease Prognosis in Breast Cancer.
Nair MG; Ramesh RS; Naidu CM; Mavatkar AD; V P S; Ramamurthy V; Somashekaraiah VM; C E A; Raghunathan K; Panigrahi A; Das M; Dhar SK; Prabhu JS
Cancers (Basel); 2023 Feb; 15(4):. PubMed ID: 36831397
[TBL] [Abstract][Full Text] [Related]
29. Circulating cell-free DNA (cfDNA) levels in BRCA1 and BRCA2 mutation carriers: A preliminary study.
Douvdevani A; Bernstein-Molho R; Asraf K; Doolman R; Laitman Y; Friedman E
Cancer Biomark; 2020; 28(3):269-273. PubMed ID: 32280079
[TBL] [Abstract][Full Text] [Related]
30. The integrity of cfDNA in follicular fluid and spent medium from embryo culture is associated with embryo grade in patients undergoing in vitro fertilization.
Pan M; Shi H; Liu Z; Dong J; Cai L; Ge Q
J Assist Reprod Genet; 2021 Dec; 38(12):3113-3124. PubMed ID: 34820723
[TBL] [Abstract][Full Text] [Related]
31. Denaturation-Enhanced Droplet Digital PCR for Liquid Biopsies.
Fitarelli-Kiehl M; Yu F; Ashtaputre R; Leong KW; Ladas I; Supplee J; Paweletz C; Mitra D; Schoenfeld JD; Parangi S; Makrigiorgos GM
Clin Chem; 2018 Dec; 64(12):1762-1771. PubMed ID: 30274976
[TBL] [Abstract][Full Text] [Related]
32. The feasibility of using liquid biopsies as a complementary assay for copy number aberration profiling in routinely collected paediatric cancer patient samples.
Van Paemel R; Vandeputte C; Raman L; Van Thorre J; Willems L; Van Dorpe J; Van Der Linden M; De Wilde J; De Koker A; Menten B; Devalck C; Vicha A; Grega M; Schleiermacher G; Iddir Y; Chicard M; van Zogchel L; Stutterheim J; Lak NSM; Tytgat GAM; Laureys G; Speleman F; De Wilde B; Lammens T; De Preter K; Van Roy N
Eur J Cancer; 2022 Jan; 160():12-23. PubMed ID: 34794856
[TBL] [Abstract][Full Text] [Related]
33. Circulating cell-free endometrial DNA level is unaltered during menstruation and in endometriosis.
Yuwono NL; Alonso A; Abbott J; Houshdaran S; Henry CE; Rodgers R; Ford CE; Warton K
Hum Reprod; 2022 Oct; 37(11):2560-2569. PubMed ID: 36166696
[TBL] [Abstract][Full Text] [Related]
34. Plasma Cell-Free DNA Integrity Assessed by Automated Electrophoresis Predicts the Achievement of Pathologic Complete Response to Neoadjuvant Chemotherapy in Patients With Breast Cancer.
Cirmena G; Ferrando L; Ravera F; Garuti A; Dameri M; Gallo M; Barbero V; Ferrando F; Del Mastro L; Garlaschi A; Friedman D; Fregatti P; Ballestrero A; Zoppoli G
JCO Precis Oncol; 2022 Feb; 6():e2100198. PubMed ID: 35201850
[TBL] [Abstract][Full Text] [Related]
35. Circulating cell-free DNA: a promising marker of regional lymphonode metastasis in breast cancer patients.
Agostini M; Enzo MV; Bedin C; Belardinelli V; Goldin E; Del Bianco P; Maschietto E; D'Angelo E; Izzi L; Saccani A; Zavagno G; Nitti D
Cancer Biomark; 2012; 11(2-3):89-98. PubMed ID: 23011155
[TBL] [Abstract][Full Text] [Related]
36. Alu cell-free DNA concentration, Alu index, and LINE-1 hypomethylation as a cancer predictor.
Park MK; Lee JC; Lee JW; Hwang SJ
Clin Biochem; 2021 Aug; 94():67-73. PubMed ID: 33901468
[TBL] [Abstract][Full Text] [Related]
37. Diagnostic Role of Cell-free DNA Integrity in Thyroid Cancer Particularly for Bethesda IV Cytology.
Higazi AM; El Hini SH; El-Sharkawy EA; Gayyed MF; Aziz NA; Matta RA
Endocr Pract; 2021 Jul; 27(7):673-681. PubMed ID: 33601025
[TBL] [Abstract][Full Text] [Related]
38. Evaluation of cfDNA as an early detection assay for dense tissue breast cancer.
Barbirou M; Miller AA; Gafni E; Mezlini A; Zidi A; Boley N; Tonellato PJ
Sci Rep; 2022 May; 12(1):8458. PubMed ID: 35589867
[TBL] [Abstract][Full Text] [Related]
39. Diagnostic Value of Serum Concentration and Integrity of Circulating Cell-Free DNA in Breast Cancer: A Comparative Study With CEA and CA15-3.
Tang Z; Li L; Shen L; Shen X; Ju S; Cong H
Lab Med; 2018 Oct; 49(4):323-328. PubMed ID: 29701836
[TBL] [Abstract][Full Text] [Related]
40. Combinations of plasma cfDNA concentration, integrity and tumor markers are promising biomarkers for early diagnosis of non-small cell lung cancer.
Ren S; Zeng G; Yi Y; Liu L; Tu H; Chai T; Hu L
Heliyon; 2023 Oct; 9(10):e20851. PubMed ID: 37860559
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
